8-K: RadNet Reports Record Q1 2026 Results, Raises Guidance

RadNet announced record first-quarter 2026 financial results, exceeding prior year performance and leading to upward revisions in full-year guidance for revenue, Adjusted EBITDA, and Free Cash Flow.

Summary

• RadNet reported record first-quarter 2026 financial results, with total company revenue reaching $575.6 million, a 22.1% increase from $471.4 million in Q1 2025.
• Total company Adjusted EBITDA was $63.3 million, up 36.3% from $46.4 million in Q1 2025.
• Digital Health segment revenue grew 51.5% to $29.1 million, with Annual Recurring Revenue (ARR) increasing to $96.9 million from $49.8 million year-over-year.
• Despite a decrease in Digital Health Adjusted EBITDA to $1.3 million due to infrastructure investments, the overall company performance was strong.
• Advanced imaging procedural volumes increased by 19.7% and same-center advanced imaging volumes grew by 8.2%.
• The company has revised its full-year 2026 guidance upwards for Imaging Center Revenue, Adjusted EBITDA, and Free Cash Flow.
• RadNet ended the quarter with a cash balance of $455.3 million and a Net Debt to Adjusted EBITDA ratio below 2.0.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with record results, significant year-over-year growth, and upward revisions to guidance, despite some segment-specific investment-related decreases.

Positives

• Total company revenue increased by 22.1% to $575.6 million in Q1 2026 compared to Q1 2025.
• Total company Adjusted EBITDA increased by 36.3% to $63.3 million in Q1 2026 compared to Q1 2025.
• Digital Health revenue saw a significant increase of 51.5% to $29.1 million.
• Annual Recurring Revenue (ARR) for Digital Health more than doubled, reaching $96.9 million at March 31, 2026.
• Aggregate advanced imaging procedural volumes increased by 19.7% and same-center advanced imaging volumes grew by 8.2%.
• Full-year 2026 guidance for Imaging Center Revenue, Adjusted EBITDA, and Free Cash Flow has been revised upwards.
• The company maintains a strong balance sheet with $455.3 million in cash and a leverage ratio below 2.0.
• The acquisition of Gleamer SAS in France is expected to enhance the clinical AI portfolio.

Negatives

• Digital Health segment Adjusted EBITDA decreased to $1.3 million from $3.7 million in Q1 2025 due to intentional infrastructure investments.
• The company reported a Net Loss of $33.5 million for Q1 2026, compared to a Net Loss of $37.9 million in Q1 2025.
• Adjusted Diluted Loss Per Share was $(0.28) for Q1 2026, compared to $(0.34) for Q1 2025.

Risks

• Impact of pandemics, severe weather, or other exogenous factors on business operations, suppliers, payors, customers, referral sources, partners, patients, and employees.
• Availability and terms of capital to fund business operations and expansion.
• Ability to service indebtedness and remain compliant with debt covenants.
• Changes in general economic conditions nationally and regionally.
• Impact of healthcare reform, legislation, regulations, or litigation on coverage or reimbursement rates.
• Labor costs and labor difficulties, including stoppages affecting operations or suppliers.
• Cybersecurity incidents or security breaches involving confidential information.
• Risks associated with mergers and acquisitions, including integration challenges and inability to realize anticipated benefits.

Future Outlook

RadNet has revised its full-year 2026 guidance upwards for Imaging Center Revenue, Adjusted EBITDA, and Free Cash Flow, reflecting strong operating trends. Digital Health guidance ranges remain unchanged.

Management Comments

• After being impacted by severe winter weather conditions in the Northeast during January and February which reduced Revenue and Adjusted EBITDA(1) by an estimated $13 million and $9 million, respectively, our business strongly rebounded in March, resulting in a Total Company Revenue increase of 22.1% and a Total Company Adjusted EBITDA(1) increase of 36.3% from last years first quarter.
• The record first quarter performance was driven by aggregate advanced imaging (MRI, CT and PET/CT) growth of 19.7% and same-center advanced imaging growth of 8.2% as compared with the first quarter of last year.
• On April 30th, we announced the commencement of a new health system joint venture with Trinity Healths Saint Alphonsus Health System initially with five outpatient imaging centers in Boise, Idaho. This relationship is a blueprint for future health system partnerships, where RadNet can bring all of its operational, clinical and digital workflow solutions to bear to streamline the patient journey and improve medical care and outcomes.
• As a result of the strong operating trends during the first quarter which have continued through early May, we are increasing 2026 Imaging Center guidance for Revenue, Adjusted EBITDA(1) and Free Cash Flow(2).
• The Digital Health division continues to gain momentum, which was further advanced with the March 2, 2026 acquisition of Gleamer SAS in France. DeepHealths clinical AI portfolio now includes interpretive solutions in virtually all imaging modalities.
• We estimate that by the end of this year, over 70% of RadNet studies could be running through clinical AI, and we expect that all of RadNets radiologist reports will be processed through DeepHealths Reporting Pro AI-powered auto-impression/summarization engine.
• RadNets balance sheet continues to be among the strongest in the diagnostic imaging industry. At quarter end, which reflected the acquisition of Gleamer and recent imaging center transactions, we had a cash balance of $455.3 million and a leverage ratio of Net Debt to Adjusted EBITDA(1) of slightly below 2.0.
• Financial leverage and liquidity will continue to be carefully managed to maintain optimal future operating flexibility.

Industry Context

StockSavvy.ai notes that RadNet's strong Q1 performance, particularly in advanced imaging volumes and digital health growth, aligns with broader industry trends towards increased utilization of diagnostic services and the integration of AI in healthcare workflows. The company's strategic partnerships and acquisitions, such as with Trinity Health and Gleamer SAS, demonstrate a proactive approach to expanding its market reach and technological capabilities within the competitive diagnostic imaging sector.

Comparison to Industry Standards

• RadNet's total company revenue growth of 22.1% in Q1 2026 significantly outpaces the general healthcare services sector growth, which typically sees single-digit percentage increases.
• The 36.3% increase in Adjusted EBITDA is a strong indicator of operational efficiency and pricing power, likely exceeding industry averages for similar outpatient service providers.
• The 51.5% revenue growth in the Digital Health segment, driven by AI solutions and ARR expansion, positions RadNet as a leader in a rapidly growing niche within healthcare technology, potentially outperforming pure-play AI software companies in terms of integration and market penetration.
• The increase in advanced imaging procedural volumes (19.7% aggregate, 8.2% same-center) suggests RadNet is capturing market share or benefiting from increased demand for these higher-value services, which is a positive trend compared to slower growth in routine imaging.

Stakeholder Impact

• Shareholders: Positive impact from record financial results, increased revenue and EBITDA, and upward revision of future guidance, potentially leading to increased shareholder value.
• Employees: Continued investment in AI and digital health solutions may lead to new opportunities and enhanced operational efficiency, though segment-specific EBITDA decreases could imply cost management focus.
• Customers/Patients: Implementation of AI solutions and new partnerships aim to improve patient journey, medical care, and outcomes.
• Suppliers: Increased operational activity and potential for new technology integration may create opportunities or require adaptation to new systems.

Next Steps

• Continue implementation of DeepHealth OS and AI-powered solutions in new health system joint ventures.
• Expand the use of DeepHealth's Reporting Pro AI-powered auto-impression/summarization engine across all radiologist reports.
• Continue to manage financial leverage and liquidity to maintain operating flexibility.
• Host conference call on May 11, 2026, to discuss Q1 2026 results.

Key Dates

Recommendation

The company delivered record Q1 results with substantial year-over-year growth in revenue and Adjusted EBITDA, significantly exceeding prior performance. The upward revision of full-year guidance across key metrics (Revenue, Adjusted EBITDA, Free Cash Flow) indicates strong operational momentum and management's confidence in sustained growth. The strategic expansion in Digital Health, evidenced by a doubling of ARR and successful acquisitions, positions RadNet favorably in a high-growth area. Despite a net loss and decreased Digital Health EBITDA due to strategic investments, the overall financial health, strong cash position, and low leverage ratio provide a solid foundation for future performance, making it an attractive investment.

Keywords

RadNet, 8-K, Q1 2026 Earnings, Diagnostic Imaging, Digital Health, Adjusted EBITDA, Revenue Growth, Financial Guidance